Article
Reproductive Biology
Zhongmian Pan, Zhongbin Luo, Hongying He, Yujie Chen, Bingbing Zhao, Zhijun Yang, Li Li
Summary: This study evaluated the clinical efficacy and safety of apatinib in patients with advanced platinum-resistant relapsed epithelial ovarian cancer. The results showed that apatinib had a higher objective response rate and disease control rate in this disease, and it prolonged progression-free survival and overall survival. Therefore, apatinib may be an effective treatment option for advanced platinum-resistant relapsed epithelial ovarian cancer.
JOURNAL OF OVARIAN RESEARCH
(2023)
Article
Chemistry, Medicinal
Qingli Cui, Yanhui Hu, Dongyang Ma, Huaimin Liu
Summary: Anlotinib showed moderate improvements in progression-free survival and overall survival in patients with platinum-resistant or platinum-refractory ovarian cancer, indicating it may be a new treatment option for this group of patients.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Oncology
Soo Jin Park, Suk-Joon Chang, Dong Hoon Suh, Tae Wook Kong, Heekyoung Song, Tae Hun Kim, Jae-Weon Kim, Hee Seung Kim, Sung-Jong Lee
Summary: This study evaluates the safety and tolerability of PHI-101 in platinum-resistant recurrent ovarian cancer. By determining the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of PHI-101, this study aims to find the recommended dose for further clinical trials. The study may contribute to developing a new combination regimen for the treatment of ovarian cancer.
Article
Oncology
Panagiotis A. Konstantinopoulos, Jung-Min Lee, Bo Gao, Rowan Miller, Jung-Yun Lee, Nicoletta Colombo, Ignace Vergote, Kelly M. Credille, Suzanne R. Young, Samuel McNeely, Xuejing Aimee Wang, Aimee Bence Lin, Ronnie Shapira-Frommer
Summary: This study aimed to evaluate the efficacy and safety of using prexasertib, a CHK1 inhibitor, in treating high-grade serous ovarian cancer. The results showed that prexasertib demonstrated durable single agent activity to a certain extent and its effects were not influenced by clinical characteristics, BRCA status, or prior therapies, including PARPi. The study also emphasized the need for alternative biomarker approaches to identify responders.
GYNECOLOGIC ONCOLOGY
(2022)
Review
Biotechnology & Applied Microbiology
Yawen Wu, Xiaoyan Zhang, Lian Li, Wen Yang, Zhifeng Yan, Chenglei Gu, Zhe Zhang, Jiahuan Zhou, Lulu Liu, Mingxia Ye, Yuanguang Meng
Summary: This case demonstrates that PROC patients may have a sustained response to triplet combination therapy with camrelizumab, fuzuloparib, and apatinib, potentially improving prognosis.
ONCOTARGETS AND THERAPY
(2022)
Article
Reproductive Biology
Zhen Yuan, Ying Zhang, Dongyan Cao, Keng Shen, Qingshui Li, Guonan Zhang, Xiaohua Wu, Manhua Cui, Ying Yue, Wenjun Cheng, Li Wang, Pengpeng Qu, Guangshi Tao, Jianqing Hou, Lixin Sun, Yuanguang Meng, Guiling Li, Changzhong Li, Huirong Shi, Yaqing Chen
Summary: This study evaluated the efficacy and safety of PLD in treating platinum-resistant and platinum-refractory relapse in patients with epithelial ovarian, fallopian tube, and peritoneal cancer. The results showed that PLD was associated with satisfactory efficacy, low frequency of adverse events, and high patient quality of life, with low baseline CA125 levels and a reduction in CA125 after the first cycle predicting satisfactory efficacy.
JOURNAL OF OVARIAN RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Xu Huang, Xiao-Yu Li, Wu-Lin Shan, Yao Chen, Qi Zhu, Bai-Rong Xia
Summary: Currently, ovarian cancer has the highest mortality rate among all gynecological cancers. The standard treatment protocol involves initial tumor cytoreductive surgery followed by platinum-based combination chemotherapy. However, traditional chemotherapy has limited efficacy due to drug resistance and recurrence. With the advent of precision medicine, molecular targeted therapy has emerged as a promising approach for ovarian cancer treatment. Genetic mutations, such as BRCA and HRD gene mutations, can guide targeted drug treatment and improve patient prognosis. This article reviews different targeted therapy sites and pathways, along with the latest research progress in preclinical and clinical trials related to ovarian cancer therapy.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Oncology
Siyu Li, Tao Wang, Xichang Fei, Mingjun Zhang
Summary: Platinum-resistant ovarian cancer is a deadly cancer with a poor prognosis, and ATR inhibitors have shown promising results in its treatment.
Article
Reproductive Biology
Katie K. Crean-Tate, Chad Braley, Goutam Dey, Emily Esakov, Caner Saygin, Alexandria Trestan, Daniel J. Silver, Soumya M. Turaga, Elizabeth V. Connor, Robert DeBernardo, Chad M. Michener, Peter G. Rose, Justin Lathia, Ofer Reizes
Summary: Therapeutic targeting of cisplatin resistant endometrioid ovarian cancer through LCKi treatment followed by LCKi-cisplatin combination therapy leads to chemosensitization to platinum chemotherapy, demonstrating increased cell viability and apoptosis, and slowed tumor growth in vivo.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Oncology
David Howard, David James, Jezabel Garcia-Parra, Belen Pan-Castillo, Jenny Worthington, Nicole Williams, Zoe Coombes, Sophie Colleen Rees, Kerryn Lutchman-Singh, Lewis W. Francis, Paul Rees, Lavinia Margarit, R. Steven Conlan, Deyarina Gonzalez
Summary: Ovarian cancer is a deadly disease that is often diagnosed late, resulting in poor prognosis. Platinum-based therapies are commonly used, but resistance to these treatments is common, making prognosis even worse. This study aimed to evaluate the effectiveness of CDK inhibitors in platinum-resistant ovarian cancer models and their potential clinical utility. The results showed that the CDK inhibitor, dinaciclib, was highly effective in both cell lines and primary cells of ovarian cancer, even more so than cisplatin. Furthermore, resistance to cisplatin did not affect the sensitivity to dinaciclib, and the two drugs had an additive effect when used together. This suggests a potential role for pan-CDK inhibitors in the treatment of advanced and platinum-resistant ovarian cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Rebecca L. Porter, Ursula A. Matulonis
Summary: Mirvetuximab soravtansine is an antibody drug conjugate used for the treatment of high grade serous ovarian cancer. It has shown high efficacy and favorable safety profile by targeting folate receptor alpha and releasing cytotoxic agents. This research holds great importance for the development of mirvetuximab combinations in platinum sensitive and newly diagnosed ovarian cancer patients.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Review
Pharmacology & Pharmacy
Shuk on Annie Leung, Panagiotis A. Konstantinopoulos
Summary: PROC is defined as disease recurrence within 6 months of completing platinum-based chemotherapy, generally associated with poor outcomes and low response rates. Recent developments in therapeutics based on biomarkers and a more nuanced understanding of DNA repair and immunologic pathways have led to novel treatment options, such as PARP inhibitors, cell cycle checkpoint inhibitors, and immune checkpoint inhibitors.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Article
Oncology
Rachel E. Kinney, Suresh Nair, Christine H. Kim, M. Bijoy Thomas, Martin DelaTorre
Summary: Platinum-resistant ovarian cancer is associated with poor prognosis and limited treatment options. Combination treatment with immunotherapy, anti-angiogenic therapy, and chemotherapy can significantly extend progression-free survival in these patients.
Article
Oncology
Rachel E. Kinney, Suresh Nair, Christine H. Kim, M. Bijoy Thomas, Martin DelaTorre
Summary: Ovarian cancer is a common gynecologic cancer in the US, and platinum-resistant disease has a poor prognosis. This study suggests that treatment with immunotherapy followed by anti-angiogenic therapy and chemotherapy can improve survival in patients with platinum-resistant ovarian cancer. The experience of three patients showed significantly longer progression-free survival compared to previous averages.
Article
Oncology
Michelle McMullen, Ainhoa Madariaga, Stephanie Lheureux
Summary: Platinum drugs are crucial in ovarian cancer treatment, but resistance is a major challenge, with complex mechanisms involving both intracellular and microenvironment factors. Clinical trials are essential for improving outcomes, and future research should focus on understanding the biology of the disease and enhancing quality of life and survival for patients.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Oncology
Zhong Zheng, Bingya Liu, Xiaohua Wu
CANCER CELL INTERNATIONAL
(2015)
Article
Oncology
Wei Chen, Qin Ma, Xiaoqin Chen, Chenyan Wang, Huijuan Yang, Yi Zhang, Shuang Ye
Summary: The study showed that most inpatient gynecologic cancer patients hoped doctors could discuss their sexual issues, and they were also willing to talk about sexual health problems and were interested in receiving basic sexual health counseling. In terms of sexual issue discussion, age, education level, and patient attitudes played a certain predictive role in whether there was a history of consultation about sexual issues.
JOURNAL OF CANCER EDUCATION
(2021)
Article
Oncology
Shuang Ye, Shuling Zhou, Wei Chen, Libing Xiang, Xiaohua Wu, Huijuan Yang
CANCER MANAGEMENT AND RESEARCH
(2020)
Article
Reproductive Biology
Wei Chen, Siyuan Zhong, Boer Shan, Shuling Zhou, Xiaohua Wu, Huijuan Yang, Shuang Ye
JOURNAL OF OVARIAN RESEARCH
(2020)
Article
Oncology
Lihua Chen, Jiajia Li, Xiaohua Wu, Zhong Zheng
Summary: The study aimed to explore the genomic abnormalities associated with uterine leiomyosarcoma (uLMS) and identify potential therapeutic targets. Analysis revealed mutational heterogeneity of uLMS and highlighted the amplification of the SHARPIN gene as a candidate oncogene in uLMS.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Wei Chen, Boer Shan, Shuling Zhou, Huijuan Yang, Shuang Ye
Summary: This study suggests that the fibrinogen/albumin ratio (FAR) may serve as a potential biochemical marker for predicting platinum resistance and survival outcomes in patients with ovarian clear cell carcinoma (OCCC).
Article
Reproductive Biology
Siyu Chen, Yong Wu, Simin Wang, Jiangchun Wu, Xiaohua Wu, Zhong Zheng
Summary: This study identifies differentially expressed genes associated with platinum therapy and prognosis in ovarian cancer, and constructs a specific risk model that can serve as effective biomarkers for evaluating platinum therapy response and predicting survival outcomes. PNLDC1, SLC5A1, and SYNM are identified as hub genes that may have potential as biomarkers in ovarian cancer treatment.
JOURNAL OF OVARIAN RESEARCH
(2022)
Article
Obstetrics & Gynecology
Wei Zhang, Zhihong Han, Ziting Li, Zhong Zheng, Xiaohua Wu
Summary: This study aimed to evaluate the impact of initial surgical treatments and surgical re-exploration on the oncological outcomes of patients with incidentally diagnosed uLMS. The results suggest that reoperation with total hysterectomy after incomplete surgery may be beneficial for patients with incidentally diagnosed uLMS.
GYNECOLOGIC AND OBSTETRIC INVESTIGATION
(2021)